Monte Rosa Therapeutics logo

Monte Rosa TherapeuticsNASDAQ: GLUE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

24 June 2021

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$540.69 M
-56%vs. 3y high
66%vs. sector
-vs. 3y high
-vs. sector
-27%vs. 3y high
63%vs. sector
-74%vs. 3y high
94%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:46:15 GMT
$8.81+$0.11(+1.26%)

Dividend

No data over the past 3 years
$4.70 M$2.62 M
$4.70 M-$30.31 M

Analysts recommendations

Institutional Ownership

GLUE Latest News

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade
zacks.com30 October 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Monte Rosa Therapeutics (GLUE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: POSITIVE

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.71 per share a year ago.

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
globenewswire.com16 May 2024 Sentiment: POSITIVE

Monte Rosa Therapeutics, Inc. ("Monte Rosa") announced the pricing of a public offering of its common stock and pre-funded warrants, with expected gross proceeds of approximately $100 million.

Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
Zacks Investment Research10 April 2024 Sentiment: POSITIVE

Monte Rosa Therapeutics (GLUE) passed our "Recent Price Strength" screen and may be an attractive option for investors seeking to capitalize on stocks showing momentum.

Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
Zacks Investment Research04 April 2024 Sentiment: POSITIVE

The consensus price target hints at a 107.8% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research22 March 2024 Sentiment: POSITIVE

Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
Zacks Investment Research19 March 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)
Zacks Investment Research24 October 2023 Sentiment: POSITIVE

Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

What type of business is Monte Rosa Therapeutics?

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

What sector is Monte Rosa Therapeutics in?

Monte Rosa Therapeutics is in the Healthcare sector

What industry is Monte Rosa Therapeutics in?

Monte Rosa Therapeutics is in the Biotechnology industry

What country is Monte Rosa Therapeutics from?

Monte Rosa Therapeutics is headquartered in United States

When did Monte Rosa Therapeutics go public?

Monte Rosa Therapeutics initial public offering (IPO) was on 24 June 2021

What is Monte Rosa Therapeutics website?

https://www.monterosatx.com

Is Monte Rosa Therapeutics in the S&P 500?

No, Monte Rosa Therapeutics is not included in the S&P 500 index

Is Monte Rosa Therapeutics in the NASDAQ 100?

No, Monte Rosa Therapeutics is not included in the NASDAQ 100 index

Is Monte Rosa Therapeutics in the Dow Jones?

No, Monte Rosa Therapeutics is not included in the Dow Jones index

When was Monte Rosa Therapeutics the previous earnings report?

No data

When does Monte Rosa Therapeutics earnings report?

The next expected earnings date for Monte Rosa Therapeutics is 08 November 2024